7.57
+0.16
+(2.23%)
As of 3:49:06 PM EST. Market open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating cash flow
-157,527.00
-149,549.00
-122,332.00
-77,880.00
-35,265.00
Investing cash flow
36,437.00
27,690.00
-155,955.00
-239,098.00
-51,127.00
Financing cash flow
201,429.00
212,577.00
328,956.00
377,089.00
92,627.00
End cash position
163,483.00
210,954.00
120,236.00
69,567.00
9,456.00
Capital expenditure
-4,534.00
-9,283.00
-13,232.00
-4,359.00
-3,424.00
Issuance of capital stock
199,257.00
210,456.00
326,495.00
378,973.00
92,616.00
Free cash flow
-162,061.00
-158,832.00
-135,564.00
-82,239.00
-38,689.00
12/31/2020 - 6/17/2021
Upgrade to start utilising 40 years of financial statements and gain so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets and cash flows - all exportable.
UpgradeRelated tickers
BEAM Beam Therapeutics Inc.
26.12
-4.25%
NTLA Intellia Therapeutics, Inc.
10.29
-2.09%
PRME Prime Medicine, Inc.
2.8100
-0.71%
CRBU Caribou Biosciences, Inc.
1.4270
+8.91%
EDIT Editas Medicine, Inc.
1.3150
-4.01%
SANA Sana Biotechnology, Inc.
3.2650
-6.45%
KPTI Karyopharm Therapeutics Inc.
0.6360
-4.23%
FATE Fate Therapeutics, Inc.
1.2900
-5.84%
RGNX REGENXBIO Inc.
8.26
+4.56%
NKTX Nkarta, Inc.
2.3350
-1.06%